Reported 3 days ago
U.S. pharmaceutical companies may initially absorb the costs from new tariffs rather than passing them to patients, as health insurers buffer the impact on out-of-pocket expenses. While tariff increases could lead to higher prices over time, manufacturers currently set prices based on market demand and are under pressure to maintain competitive prices, especially for generic drugs, which have thinner margins. The potential increase in costs could affect investments in research and development, but firms are already working on expanding domestic production.
Source: YAHOO